1:04 PM
 | 
Apr 18, 2019
 |  BC Innovations  |  Translation in Brief

Agenus scales the AI ALPS

How Agenus’ machine learning platform helps pick combos for clinical testing

Agenus is using its artificial intelligence, machine learning platform to match cancer patients with the best monotherapy or combination therapy it has, and to uncover mechanisms of resistance to develop new therapies using non-responder data.

The platform, called ALPS (Adaptive Learning Platform Systems), combines patient data from Agenus’ clinical trials with preclinical data from cellular and in vivo assays designed by Thomas Horn, a senior scientist at Agenus.

The patient response data is taken from trials of Agenus’ checkpoint inhibitors and cancer vaccines. The company collects T cells from patients’ tumor and blood samples and performs immunohistochemistry and next-generation sequencing analyses to identify markers of immune fitness.

“We want to understand how...

Read the full 535 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Innovations

Article Purchase

$100 USD
More Info >